Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of rovadicitinib versus investigator's choice in third-line or later moderate-to-severe chronic graft-versus-host disease
CTR20243691Phase 3Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rovadicitinib in chronic graft-versus-host disease (cGVHD), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Nov 2024; status: active.
02
Drugs
rovadicitinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on CTR20243691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243691.